SLC5A2 and hydrops fetalis: Finally, since it is rational to combine DPP4is with SGLT-2 inhibitors, fixed-dose combinations have been developed [27], and because combinations with SGLT2is are associated with a lower risk of HF [28, 29], we examined whether HF rates were moderated in reports of a DPP4i used in combination with a SGLT2i.